Posted by Michael Wonder on 08 Feb 2017
Institute for Clinical and Economic Review to review treatments for ovarian cancer in upcoming report
8 February 2017 - Preliminary list of drugs to be reviewed includes rucaparib, niraparib and olaparib.
The Institute for Clinical and Economic Review (ICER) will develop a report assessing the comparative clinical effectiveness and value of emerging therapies for treatment of ovarian cancer. The report will include a systematic review of the clinical effectiveness and cost-effectiveness of selected treatments. While awaiting further discussion with patient groups, clinical experts, and other stakeholders to help develop a formal scope for this review, our preliminary intent is to evaluate the emerging treatments rucaparib (Rubraca, Clovis), niraparib (Tesaro) and olaparib (Lynparza, AstraZeneca). This list may change as the scope develops.
Additional information on the preliminary list of treatments to be reviewed will be posted as part of a draft scoping document scheduled to be released for public comment on 6 March 2017.
